- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05923853
Electronic Optimization of Inspired Oxygen During Mechanical Ventilation, a Pragmatic Randomized Trial (OPTI-Oxygen)
April 8, 2025 updated by: Sonal Pannu, Ohio State University
Electronic Optimization of Inspired Oxygen During Mechanical Ventilation, a Pragmatic Randomized Trial
OPTI-Oxygen is a single center, stepped wedged, cluster-randomized, un-blinded, pragmatic, comparing the use of a combined inspired oxygen (FiO2) and peripheral oxygen saturation (SpO2) titration strategy utilizing electronic health records (EHR) based electronic alerts (e-alerts) for respiratory therapists in mechanically ventilated critically ill adults.
All eligible mechanically ventilated patients, FiO2 titration and SpO2 goal range will be based on the correlation between SpO2 and arterial oxygen saturation (SaO2).
E-alerts will be sent in the intervention arm as reminders for FiO2 titration.
In the control arm, patients will have oxygen titrated per current standard of care (SpO2=88-92%, titrate FiO2 at least every 4 hours).
Study Overview
Status
Suspended
Conditions
Intervention / Treatment
Detailed Description
We will conduct a single center, stepped wedged, cluster-randomized, un-blinded, pragmatic, comparing the use of a combined inspired oxygen (FiO2) and peripheral oxygen saturation (SpO2) titration strategy utilizing electronic health records (EHR) based electronic alerts (e-alerts) for respiratory therapists in mechanically ventilated critically ill adults.
The participating intensive care units (ICU) will be medical, cancer, surgical (general surgery and trauma) and coronary critical care at the Ohio State University, Wexner Medical Center and James Cancer Hospital (128 beds).
In this stepped wedge design, there will be nested randomization.
A 12-13 bed pod within each of the 4 ICU's will be randomized as "step".
Each 12-13 bed pod, geographically located within a unit will serve as a cluster and transition from control to intervention will occur every 6 weeks, with an initial 2 week implementation period.
All intubated patients meeting inclusion criteria in a particular cluster will be in the intervention or control group per the assignment of that cluster.
In the intervention arm, arterial oxygen saturation (SaO2) and peripheral oxygen saturation (SpO2) will be initially noted.
Based on the correlation between the SaO2 and SpO2 the optimal oxygenation range will be determined.
Then E-alerts will be used to monitor oxygenation for patients in the intervention arm, based SpO2 values generated by the patient due to the FiO2 given to the patient through the ventilator.
E-Alerts search for SpO2 and FiO2 values every minute to evaluate if they meet criteria for optimal oxygenation.
If in a 45 minute period 80% of values for both SpO2 and FiO2 values are do not meet target range then an e-alert (text message) is sent to the respiratory therapy cisco phones recommending that oxygen needs to be titrated.
Once an e-alert is sent, the respiratory therapist has 45 minutes for adjusting oxygen.
Then the e-alert continues to monitor FiO2 and SpO2 values in this manner for every 45 minute period until the ventilator is attached to the patient.
(Details in study procedures, section 5).
In the control arm, FiO2 titration will be assessed by the optimal oxygenation criteria by current standard of care.
This is done by following the ICU ventilator management guidelines.
Per the ventilator management guidelines assessment for FiO2 titration is recommended at least once in 4 hours to maintain oxygenation with the optimal range.
Treatment allocation (SpO2 and FiO2 targeted titration) will cross over to a new cluster at the conclusion of each period.
Protocol adherence will be monitored.
Data will be collected until hospital discharge.
The study will be carried about with waiver of consent, because the target ranges studied are used as part of routine clinical care in the ICU, and are interventions to which patients would be exposed even if not participating in the study.
There is clinical equipoise, i.e. have inadequate prior data to suggest the superiority of one approach over the other.
Additionally, patients in the trial would be expected to receive similar oxygen therapy in an unstructured manner if they were not in the trial.
Study Type
Interventional
Enrollment (Estimated)
936
Phase
- Not Applicable
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
Ohio
-
Columbus, Ohio, United States, 43201
- The Ohio State Wexner Medical Center
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
- Adult
- Older Adult
Accepts Healthy Volunteers
No
Description
Inclusion Criteria:
- Age >18 years
- Presence of mechanical ventilation
Exclusion Criteria:
- Pregnancy
- Prisoner status
- Pneumothorax
- Carbon monoxide poisoning
- Hyperbaric oxygen therapy
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Prevention
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Double
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
|---|---|
|
Experimental: Oxygen (FiO2) Titration per E-alerts
All eligible mechanically ventilated patients, FiO2 titration and SpO2 goal range will be based on the correlation between SpO2 and arterial oxygen saturation (SaO2).
E-alerts will be sent in the intervention arm as reminders for FiO2 titration.
|
In the intervention arm, arterial oxygen saturation (SaO2) and peripheral oxygen saturation (SpO2) will be initially noted.
Based on the correlation between the SaO2 and SpO2 the optimal oxygenation range will be determined.
E-alerts will then be used to monitor oxygenation for patients in the intervention arm, based on SpO2 values generated by the patient due to the FiO2 given to the patient through the ventilator.
Once an e-alert is sent, the respiratory therapist has 45 minutes for adjusting oxygen.
Then the e-alert continues to monitor FiO2 and SpO2 values in this manner for every 45 minute period until the ventilator is attached to the patient.
|
|
No Intervention: Oxygen Titration per Standard of Care
In the control arm, patients will have oxygen titrated per current standard of care (SpO2=88-92%, titrate FiO2 at least every 4 hours).
Physician place oxygen titration orders in EMR and respiratory therapists conduct FiO2 titration without electronic alerts.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Proportion of time during mechanical ventilation spent within the target range, SpO2 of 90-94% (conservative) or SpO2 of 93-97% (liberal) at any FiO2 in respective algorithms.
Time Frame: through study completion, average of 28-30 days
|
Percent time during mechanical ventilation in target range.
|
through study completion, average of 28-30 days
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Length of ICU stay
Time Frame: through study completion, average of 28-30 days
|
Total number of days in the ICU.
|
through study completion, average of 28-30 days
|
|
Length of hospital stay
Time Frame: through study completion, average of 28-30 days
|
Total number of days in the hospital.
|
through study completion, average of 28-30 days
|
|
Hospital mortality
Time Frame: through study completion, average of 28-30 days
|
Dead or alive at hospital discharge.
|
through study completion, average of 28-30 days
|
|
Ventilator-Free Days
Time Frame: through study completion, average of 28-30 days
|
Alive and free from ventilator support at day 28.
|
through study completion, average of 28-30 days
|
|
Vasopressor-Free Days
Time Frame: through study completion, average of 28-30 days
|
Alive and free from vasopressor support at day 28.
|
through study completion, average of 28-30 days
|
|
ICU-Free Days
Time Frame: through study completion, average of 28-30 days
|
Alive and out of the ICU at day 28.
|
through study completion, average of 28-30 days
|
|
New onset arrhythmia when SpO2<90%
Time Frame: through study completion, average of 28-30 days
|
Arrhythmia onset during hypoxemia.
|
through study completion, average of 28-30 days
|
|
Proportion of time with SpO2 > 94% or SpO2 > 97% with FiO2 ≤ 0.4 in respective algorithms.
Time Frame: through study completion, average of 28-30 days
|
Percent time during mechanical ventilation above target range.
|
through study completion, average of 28-30 days
|
|
Proportion of time with time with SpO2 < 90% or SpO2 < 93% in respective algorithms.
Time Frame: through study completion, average of 28-30 days
|
Percent time during mechanical ventilation below target range.
|
through study completion, average of 28-30 days
|
|
Change to comfort care status (DNRCC) and time to DNRCC after enrollment.
Time Frame: until hospital discharge or death befoe hospital discharge, upto 60 days
|
Change to comfort care status after enrollment will be recorded and analyzed as a dichotomous outcome.
Time to DNRCC after enrollment will be evaluated in an exploratory nature using appropriate time-to-event models.
Hospital mortality while in comfort care status will also be examined as an exploratory endpoint.
|
until hospital discharge or death befoe hospital discharge, upto 60 days
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Collaborators
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
January 15, 2024
Primary Completion (Estimated)
August 31, 2025
Study Completion (Estimated)
May 1, 2026
Study Registration Dates
First Submitted
June 5, 2023
First Submitted That Met QC Criteria
June 20, 2023
First Posted (Actual)
June 28, 2023
Study Record Updates
Last Update Posted (Actual)
April 11, 2025
Last Update Submitted That Met QC Criteria
April 8, 2025
Last Verified
April 1, 2025
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 2023H0016
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
YES
IPD Plan Description
Deidentified dataset will be shared after the completion of data analysis of the last patient is enrolled.
IPD Sharing Time Frame
1 year after enrollment of the last patient.
Data will be available for 5 years
IPD Sharing Access Criteria
To be determined
IPD Sharing Supporting Information Type
- STUDY_PROTOCOL
- SAP
- ICF
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Hyperoxia
-
Northern State Medical UniversityCompletedHypocapnia | Response to HyperoxiaRussian Federation
-
Copenhagen University Hospital, HvidovreThe Ludvig & Sara Elsass FoundationCompletedResponse to HyperoxiaDenmark
-
Istanbul UniversityCompleted
-
Istinye UniversityNot yet recruitingHyperoxia / High FiO₂ Exposure | Uric Acid/Albumin Ratio (UAR)
-
Haute Ecole Bruxelles-BrabantCompletedHigh Intensity Interval Training | Hypoxia | Interval Training | VO2max | HIIT | Hyperoxia / High FiO₂ ExposureBelgium
-
Masimo CorporationCompleted
-
Zonguldak Bulent Ecevit UniversityCompleted
-
SIZ NursingCompleted
-
University Hospital of CologneUnknown
Clinical Trials on FiO2 titration using electronic alert system
-
Seattle Children's HospitalCompleted
-
Scott C. Woller, MDJanssen PharmaceuticalsRecruitingDeep Vein Thrombosis | Hospitalism | Venous Thromboembolic Disease | Pulmonary Embolism and ThrombosisUnited States
-
Thomas RivaCompletedApnea | Anesthesia | Intubation Complication | Children, Only | Atelectasis | Ventilation Therapy; Complications | Apnea InfantSwitzerland
-
University of MichiganCompletedCerebral HypoperfusionUnited States
-
University of MichiganUniversity of Manitoba; Washington University School of Medicine; University... and other collaboratorsCompletedAwareness During General AnesthesiaUnited States
-
South Tees Hospitals NHS Foundation TrustVapotherm, Inc.RecruitingPreterm BirthUnited Kingdom
-
St. Louis UniversityWithdrawnHypotension | AnesthesiaUnited States
-
Auckland City HospitalRecruitingDelirium | Anesthesia | Cognitive Decline | Cognition Disorder | Surgery-Complications | Delirium, PostoperativeNew Zealand
-
National Taiwan University HospitalCompletedThoracic SurgeryTaiwan
-
Joint Stock Company European Medical CentreRecruiting